Towards an understanding of the role of p53 in adrenocortical carcinogenesis

Molecular and Cellular Endocrinology

Volumn 351, Issue 1, 2012, Pages 101-110

  Wasserman, Jonathan D ^a,b   Zambetti, Gerard P ^c   Malkin, David ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ACC; Adrenocortical carcinoma; P53; Pediatric

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADRENAL CORTEX CARCINOMA; ALLELE; AMINO ACID SUBSTITUTION; BRAZIL; CANCER EPIDEMIOLOGY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; FAMILIAL CANCER; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENE TARGETING; GENETIC EPIDEMIOLOGY; GENETIC SCREENING; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HETEROZYGOSITY; HUMAN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PENETRANCE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ALLELES; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; LI-FRAUMENI SYNDROME; ORGAN SPECIFICITY; PENETRANCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857111395     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.09.010     Document Type: Review

References (133)

1. Achatz M.I., Olivier M., Le Calvez F., et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 2007, 245(1-2):96-102.
2. Almeida L.O., Custodio A.C., Pinto G.R., et al. Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. Genet. Mol. Res. 2009, 8(1):8-18.
3. Altshuler D.M., Gibbs R.A., Peltonen L., et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010, 467(7311):52-58.
4. American Cancer Society, 2010. Cancer Facts & Figures 2010.
5. Assumpcao, J.G., Seidinger, A.L., Mastellaro, M.J. et al., 2008. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil, BMC Cancer. 8357.
6. Barzon L., Chilosi M., Fallo F., et al. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur. J. Endocrinol. 2001, 145(2):207-212.
7. Berthon A., Sahut-Barnola I., Lambert-Langlais S., et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum. Mol. Genet. 2010, 19(8):1561-1576.
8. Boeckler F.M., Joerger A.C., Jaggi G., et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. USA 2008, 105(30):10360-10365.
9. Boehme K.A., Blattner C. Regulation of p53-insights into a complex process. Crit. Rev. Biochem. Mol. Biol. 2009, 44(6):367-392.
10. Boldrini L., Gisfredi S., Ursino S., et al. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. Oncol. Rep. 2008, 19(3):771-773.
11. Bond G.L., Hu W., Bond E.E., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119(5):591-602.
12. Bond G.L., Hu W., Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005, 65(13):5481-5484.
13. Bougeard G., Baert-Desurmont S., Tournier I., et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J. Med. Genet. 2006, 43(6):531-533.
14. Bulavin D.V., Saito S., Hollander M.C., et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 1999, 18(23):6845-6854.
15. Cecchinelli B., Porrello A., Lazzari C., et al. Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. Cell Death Differ. 2006, 13(11):1994-1997.
16. Choong M.L., Yang H., Lee M.A., et al. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle 2009, 8(17):2810-2818.
17. Costa, S., Pinto, D., Pereira, D. et al., 2008. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer, BMC Cancer. 832.
18. Custodio G., Taques G.R., Figueiredo B.C., et al. Increased Incidence of Choroid Plexus Carcinoma Due to the Germline TP53 R337H Mutation in Southern Brazil. PLoS One 2011, 6(3):e18015.
19. Dai C., Gu W. P53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med. 2010, 16(11):528-536.
20. de Reynies A., Assie G., Rickman D.S., et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 2009, 27(7):1108-1115.
21. Dearth L.R., Qian H., Wang T., et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 2007, 28(2):289-298.
22. Demma M., Maxwell E., Ramos R., et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J. Biol. Chem. 2010, 285(14):10198-10212.
23. den Reijer P.M., Maier A.B., Westendorp R.G., et al. Influence of the TP53 codon 72 polymorphism on the cellular responses to X-irradiation in fibroblasts from nonagenarians. Mech. Ageing Dev. 2008, 129(4):175-182.
24. DiGiammarino E.L., Lee A.S., Cadwell C., et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat. Struct. Biol. 2002, 9(1):12-16.
25. Ding K., Lu Y., Nikolovska-Coleska Z., et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 2006, 49(12):3432-3435.
26. Doghman M., Karpova T., Rodrigues G.A., et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol. Endocrinol. 2007, 21(12):2968-2987.
27. Donehower L.A., Harvey M., Slagle B.L., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356(6366):215-221.
28. Dumont P., Leu J.I., Della Pietra A.C., et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003, 33(3):357-365.
29. Else T., Giordano T.J., Hammer G.D. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2008, 93(4):1442-1449.
30. Else T., Trovato A., Kim A.C., et al. Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell 2009, 15(6):465-476.
31. Elyada E., Pribluda A., Goldstein R.E., et al. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 2011, 470(7334):409-413.
32. Figueiredo B.C., Sandrini R., Zambetti G.P., et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J. Med. Genet. 2006, 43(1):91-96.
33. Figueiredo B.C., Stratakis C.A., Sandrini R., et al. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J. Clin. Endocrinol. Metab. 1999, 84(3):1116-1121.
34. Foster B.A., Coffey H.A., Morin M.J., et al. Pharmacological rescue of mutant p53 conformation and function. Science 1999, 286(5449):2507-2510.
35. Frank A.K., Leu J.I., Zhou Y., et al. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol. Cell. Biol. 2011, 31(6):1201-1213.
36. Gemignani F., Moreno V., Landi S., et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004, 23(10):1954-1956.
37. Giordano T.J., Kuick R., Else T., et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 2009, 15(2):668-676.
38. Giordano T.J., Thomas D.G., Kuick R., et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 2003, 162(2):521-531.
39. Goodman J.E., Hofseth L.J., Hussain S.P., et al. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ. Mol. Mutagen. 2004, 44(1):3-9.
40. Grasberger B.L., Lu T., Schubert C., et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 2005, 48(4):909-912.
41. Hainaut P., Hollstein M. P53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 2000, 77:81-137.
42. Herrmann L., Heinze B., Fassnacht M., et al. TP53 and Adrenocortical Cancer-Analysis of Germline Mutations and Polymorphic Changes in 140 Patients, 3rd International Adrenal Cancer Symposium: From Molecular Pathogenesis to Clinical Outcome 2011, Wurzburg, Germany.
43. Hock A., Vousden K.H. Regulation of the p53 pathway by ubiquitin and related proteins. Int. J. Biochem. Cell Biol. 2010, 42(10):1618-1621.
44. Hollstein M., Hainaut P. Massively regulated genes: the example of TP53. J. Pathol. 2010, 220(2):164-173.
45. Hollstein M., Moeckel G., Hergenhahn M., et al. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat. Res. 1998, 405(2):145-154.
46. Huang C., Zhang X.M., Tavaluc R.T., et al. The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol. Ther. 2009, 8(22):2186-2193.
47. Itahana K., Mao H., Jin A., et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007, 12(4):355-366.
48. Jacks T., Remington L., Williams B.O., et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4(1):1-7.
49. James L.A., Kelsey A.M., Birch J.M., et al. Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization. Br. J. Cancer 1999, 81(2):300-304.
50. Jones S.N., Roe A.E., Donehower L.A., et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378(6553):206-208.
51. Kakudo Y., Shibata H., Otsuka K., et al. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res. 2005, 65(6):2108-2114.
52. Kato S., Han S.Y., Liu W., et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA 2003, 100(14):8424-8429.
53. Keeney D.S., Jenkins C.M., Waterman M.R. Developmentally regulated expression of adrenal 17 alpha-hydroxylase cytochrome P450 in the mouse embryo. Endocrinology 1995, 136(11):4872-4879.
54. Kjellman M., Kallioniemi O.P., Karhu R., et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res. 1996, 56(18):4219-4223.
55. Klein C., Vassilev L.T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 2004, 91(8):1415-1419.
56. Kruse J.P., Gu W. Modes of p53 regulation. Cell 2009, 137(4):609-622.
57. Lain S., Hollick J.J., Campbell J., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008, 13(5):454-463.
58. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358(6381):15-16.
59. Lang G.A., Iwakuma T., Suh Y.A., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119(6):861-872.
60. Latronico A.C., Pinto E.M., Domenice S., et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 2001, 86(10):4970-4973.
61. Laurell C., Velazquez-Fernandez D., Lindsten K., et al. Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur. J. Endocrinol. 2009, 161(1):141-152.
62. Lavigueur A., Maltby V., Mock D., et al. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 1989, 9(9):3982-3991.
63. Lee J.T., Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010, 17(1):86-92.
64. Li F.P., Fraumeni J.F., Mulvihill J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988, 48(18):5358-5362.
65. Li X., Dumont P., Della Pietra A., et al. The codon 47 polymorphism in p53 is functionally significant. J. Biol. Chem. 2005, 280(25):24245-24251.
66. Libe R., Groussin L., Tissier F., et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin. Cancer Res. 2007, 13(3):844-850.
67. Lomax M.E., Barnes D.M., Hupp T.R., et al. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene 1998, 17(5):643-649.
68. Longui C.A., Lemos-Marini S.H., Figueiredo B., et al. Inhibin alpha-subunit (INHA) gene and locus changes in paediatric adrenocortical tumours from TP53 R337H mutation heterozygote carriers. J. Med. Genet. 2004, 41(5):354-359.
69. Lustbader E.D., Williams W.R., Bondy M.L., et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am. J. Hum. Genet. 1992, 51(2):344-356.
70. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250(4985):1233-1238.
71. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127(7):1323-1334.
72. Masereel B., Pochet L., Laeckmann D. An overview of inhibitors of Na(+)/H(+) exchanger. Eur. J. Med. Chem. 2003, 38(6):547-554.
73. Matzuk M.M., Finegold M.J., Mather J.P., et al. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc. Natl. Acad. Sci. USA 1994, 91(19):8817-8821.
74. Michalkiewicz E., Sandrini R., Figueiredo B., et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J. Clin. Oncol. 2004, 22(5):838-845.
75. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378(6553):203-206.
76. Munro L.M., Kennedy A., McNicol A.M. The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. J. Endocrinol. 1999, 161(2):341-347.
77. Ohgaki H., Kleihues P., Heitz P.U. P53 mutations in sporadic adrenocortical tumors. Int. J. Cancer 1993, 54(3):408-410.
78. Ohkubo S., Tanaka T., Taya Y., et al. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. J. Biol. Chem. 2006, 281(25):16943-16950.
79. Olive K.P., Tuveson D.A., Ruhe Z.C., et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119(6):847-860.
80. Olivier M., Goldgar D.E., Sodha N., et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003, 63(20):6643-6650.
81. Palani, C.D., Beck, J.F. and Sonnemann, J., 2010. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression, Invest New Drugs.
82. Palmero E.I., Achatz M.I., Ashton-Prolla P., et al. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr. Opin. Oncol. 2010, 22(1):64-69.
83. Palmero E.I., Schuler-Faccini L., Caleffi M., et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 2008, 261(1):21-25.
84. Petitjean A., Achatz M.I., Borresen-Dale A.L., et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26(15):2157-2165.
85. Petitjean A., Mathe E., Kato S., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28(6):622-629.
86. Pinto E.M., Ribeiro R.C., Kletter G.B., et al. Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor. Fam. Cancer 2011, 10(1):141-146.
87. Pinto G.R., Yoshioka F.K., Silva R.L., et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet. Mol. Res. 2008, 7(1):207-216.
88. Popowicz G.M., Czarna A., Wolf S., et al. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 2010, 9(6).
89. Portwine C. P53-the link between inflammation and cancer?. Pediatr. Res. 2000, 47(5):573.
90. Ragazzon B., Libe R., Gaujoux S., et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010, 70(21):8276-8281.
91. Rao B., van Leeuwen I.M., Higgins M., et al. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget 2010, 1(7):639-650.
92. Rao C.V., Steele V.E., Swamy M.V., et al. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res. 2009, 69(20):8175-8182.
93. Reed D., Shen Y., Shelat A.A., et al. Identification and characterization of the first small molecule inhibitor of MDMX. J. Biol. Chem. 2010, 285(14):10786-10796.
94. Reincke M., Karl M., Travis W.H., et al. P53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 1994, 78(3):790-794.
95. Ribeiro R.C., Sandrini F., Figueiredo B., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl. Acad. Sci. USA 2001, 98(16):9330-9335.
96. Riley T., Sontag E., Chen P., et al. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9(5):402-412.
97. Rinaldo C., Prodosmo A., Mancini F., et al. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol. Cell. 2007, 25(5):739-750.
98. Rippin T.M., Bykov V.J., Freund S.M., et al. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002, 21(14):2119-2129.
99. Roh J.L., Kang S.K., Minn I., et al. P53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol. 2011, 47(1):8-15.
100. Ruijs M.W., Schmidt M.K., Nevanlinna H., et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur. J. Hum. Genet. 2007, 15(1):110-114.
101. Salvioli S., Bonafe M., Barbi C., et al. P53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 2005, 4(9):1264-1271.
102. Schetter A.J., Heegaard N.H., Harris C.C. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31(1):37-49.
103. SEER (Surveillance Epidemiology and End Results) Program, SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2010 Sub (1973-2008) - Linked To County Attributes - Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission.
104. Seidinger A.L., Mastellaro M.J., Paschoal Fortes F., et al. Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil. Cancer 2011, 117(10):2228-2235.
105. Shlien A., Tabori U., Marshall C.R., et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc. Natl. Acad. Sci. USA 2008, 105(32):11264-11269.
106. Slater E.P., Diehl S.M., Langer P., et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur. J. Endocrinol. 2006, 154(4):587-598.
107. Stephan E.A., Chung T.H., Grant C.S., et al. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol. Cancer Ther. 2008, 7(2):425-431.
108. Tabori U., Nanda S., Druker H., et al. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res. 2007, 67(4):1415-1418.
109. Takekawa M., Adachi M., Nakahata A., et al. P53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 2000, 19(23):6517-6526.
110. Teufel D.P., Bycroft M., Fersht A.R. Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene 2009, 28(20):2112-2118.
111. Thomas M., Kalita A., Labrecque S., et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell. Biol. 1999, 19(2):1092-1100.
112. Tinat, J., Bougeard, G., Baert-Desurmont, S. et al., 2009. 2009 version of the Chompret criteria for Li Fraumeni syndrome, J Clin Oncol. 27(26), e108-9; author reply e110.
113. Tracey W.R., Allen M.C., Frazier D.E., et al. Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc. Drug Rev. 2003, 21(1):17-32.
114. Van Leeuwen I.M., Higgins M., Campbell J., et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2011, 10(10).
115. Van Weerden W.M., Bierings H.G., Van Steenbrugge G.J., et al. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci. 1992, 50(12):857-861.
116. Varley J.M., McGown G., Thorncroft M., et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am. J. Hum. Genet. 1999, 65(4):995-1006.
117. Vassilev L.T. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004, 3(4):419-421.
118. Vassilev L.T., Vu B.T., Graves B., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303(5659):844-848.
119. Ventura A., Kirsch D.G., McLaughlin M.E., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445(7128):661-665.
120. Vilborg A., Wilhelm M.T., Wiman K.G. Regulation of tumor suppressor p53 at the RNA level. J. Mol. Med. 2010, 88(7):645-652.
121. Villani, A., Novokment, A. and Malkin, D., 2011. Lancet Oncol.
122. Wagner J., Portwine C., Rabin K., et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J. Natl. Cancer Inst. 1994, 86(22):1707-1710.
123. Wajchenberg B.L., Albergaria Pereira M.A., Medonca B.B., et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000, 88(4):711-736.
124. Wang-Gohrke S., Weikel W., Risch H., et al. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br. J. Cancer 1999, 81(1):179-183.
125. West A.N., Neale G.A., Pounds S., et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res. 2007, 67(2):600-608.
126. West A.N., Ribeiro R.C., Jenkins J., et al. Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. Cancer Res. 2006, 66(10):5056-5062.
127. Whibley C., Pharoah P.D., Hollstein M. P53 polymorphisms: cancer implications. Nat. Rev. Cancer 2009, 9(2):95-107.
128. Wooten M.D., King D.K. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993, 72(11):3145-3155.
129. Xue W., Zender L., Miething C., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445(7128):656-660.
130. Yang Y., Ludwig R.L., Jensen J.P., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005, 7(6):547-559.
131. Zambetti G.P. The p53 mutation «gradient effect» and its clinical implications. J. Cell. Physiol. 2007, 213(2):370-373.
132. Zhao J., Speel E.J., Muletta-Feurer S., et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am. J. Pathol. 1999, 155(4):1039-1045.
133. Zheng S.J., Lamhamedi-Cherradi S.E., Wang P., et al. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 2005, 54(5):1423-1428.